A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.

ABSTRACT:

Background

Brain metastasis from breast cancer presents a significant threat to women's health and quality of life. Capecitabine and sunitinib have shown some activity in this setting; therefore, we conducted a single-arm phase II trial with these agents.

Methods

Patients with breast cancer and central nervous system (CNS) metastases received whole-brain radiotherapy concurrently with capecitabine (1,000 mg/m(2) per day for 14 consecutive days), followed by concomitant capecitabine (2,000 mg/m(2) per day for 2 weeks followed by a 1-week break) and sunitinib (37.5 mg daily, continuously). The primary endpoint was progression-free survival (PFS).

Results

Of 25 planned patients that would be required to detect a 4-month improvement (from 5 to 9 months) in median PFS with

SUBMITTER: Niravath P 

PROVIDER: S-EPMC4294610 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature